Literature DB >> 17625975

Fulminant hepatic failure secondary to erlotinib.

Weitian Liu1, Frederick L Makrauer, Amir A Qamar, Pasi A Jänne, Robert D Odze.   

Abstract

Erlotinib is a tyrosine kinase inhibitor recently approved by the Food and Drug Administration for the treatment of non-small-cell lung cancer and pancreatic cancer. We report a case of a patient with stage IV non-small-cell lung cancer who died of fulminant hepatic failure as a result of treatment with erlotinib.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17625975     DOI： 10.1016/j.cgh.2007.04.014

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


  11 in total

1.  Hepatocellular carcinoma: the place of new medical therapies.

Authors:  Markus Peck-Radosavljevic
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

2.  Three cases of severe hepatic impairment caused by erlotinib.

Authors:  Yi-Sheng Huang; She-Juan An; Zhi-Hong Chen; Yi-Long Wu
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

Review 3.  Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.

Authors:  Richard G Abramson; Vandana G Abramson; Emily Chan; Leora Horn; Vicki L Keedy; William Pao; Jeffrey A Sosman
Journal:  AJR Am J Roentgenol       Date:  2013-03       Impact factor: 3.959

4.  Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile.

Authors:  Xiaohai Li; Theodore M Kamenecka; Michael D Cameron
Journal:  Drug Metab Dispos       Date:  2010-04-09       Impact factor: 3.922

Review 5.  Metabolism considerations for kinase inhibitors in cancer treatment.

Authors:  Derek R Duckett; Michael D Cameron
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

6.  Reactivation of hepatitis B virus after withdrawal of erlotinib.

Authors:  N Bui; I Wong-Sefidan
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

7.  Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.

Authors:  Cen Xie; Jialan Zhou; Zitao Guo; Xingxing Diao; Zhiwei Gao; Dafang Zhong; Haoyuan Jiang; Lijia Zhang; Xiaoyan Chen
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

8.  Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission.

Authors:  Satoshi Ohno; Yoshiteru Sumiyoshi; Katsuyoshi Hashine; Akitomi Shirato; Satoru Kyo; Masaki Inoue
Journal:  Evid Based Complement Alternat Med       Date:  2011-04-18       Impact factor: 2.629

9.  Systemic cancer therapy: achievements and challenges that lie ahead.

Authors:  Michael O Palumbo; Petr Kavan; Wilson H Miller; Lawrence Panasci; Sarit Assouline; Nathalie Johnson; Victor Cohen; Francois Patenaude; Michael Pollak; R Thomas Jagoe; Gerald Batist
Journal:  Front Pharmacol       Date:  2013-05-07       Impact factor: 5.810

10.  Acute Fatal Liver Toxicity under Erlotinib.

Authors:  Sabina Schacher-Kaufmann; Miklos Pless
Journal:  Case Rep Oncol       Date:  2010-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.